ELTX Elicio Therapeutics, Inc.
Company Analysis
Latest News
Elicio Therapeutics reports second quarter 2026 loss of $8.2M as lead candidate misses Phase 2 endpoint
Elicio Therapeutics reported financial results for the second quarter of 2026, marked by a strategic pivot after its lead candidate, ELI-002 7P, failed to meet...
Elicio Therapeutics Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Elicio Therapeutics is expected to report a consensus loss of $0.53 per share on zero revenue, with the stock trading near $2.85 against a robust analyst price...
🟢 Elicio Therapeutics is trading 5.3% up today as shares rebound with Moti Investments disclosing a 6.1% stake
Elicio Therapeutics is trading 5.3% up today at $3.20. The stock is rebounding from recent selling pressure, potentially buoyed by a significant new...
🔴 Elicio Therapeutics is trading 5.5% down today as investors weigh capital raise and trial setbacks
Elicio Therapeutics is trading 5.5% down at $2.94 as investors continue to digest the company's recent capital raise and clinical trial setbacks. • The...
🔴 Elicio Therapeutics is trading 5.5% down today following recent capital raises and broader biotech weakness
Elicio Therapeutics is trading 5.5% down at $3.11 amid continued choppy trading following its early-July capital raise and broader biotech sector weakness. •...
🔴 Elicio Therapeutics is trading 5% down today amid post-financing volatility and sector weakness
Elicio Therapeutics is trading 5% down at $3.30 amid ongoing post-financing volatility and broad biotech sector weakness. • The stock continues to see choppy...
🟢 ELTX makes sharp 13.3% jump
ELTX is trading at $3.17, up 13.3% versus the comparison close of $2.80 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 ELTX is trading 8.6% up today after closing $15M registered direct offering
ELTX is trading 8.6% up today at $3.04 after announcing the successful closing of a $15 million registered direct offering involving common stock and...
🟢 ELTX is trading 10.7% up today after closing a $15 million registered direct offering
ELTX is trading at $3.10 (10.7% up) after Elicio Therapeutics announced the closing of a $15 million registered direct offering on July 7, 2026. • The...
🟢 ELTX Rises 6.4% After Closing $15 Million Registered Direct Offering
• ELTX is trading at $2.98 (6.4% up) in after-hours trading, rebounding from a steep regular-session decline to $2.80. • Elicio Therapeutics announced the...
🔴 ELTX makes sharp 10.2% drop
ELTX is trading at $2.96, down 10.2% versus the comparison close of $3.29 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 ELTX is trading 5.2% down today on dilution concerns following a $15M offering
ELTX is trading 5.2% down at $3.12 as investors weigh the impact of a recent capital raise against clinical trial progress. • The stock is pulling back...
🟢 ELTX is trading 5.6% up today following a $15M offering and recent clinical trial volatility
ELTX is trading 5.59% up at $3.40 in pre-market following a turbulent stretch tied to financing updates and clinical data. • Elicio Therapeutics recently...
🔴 ELTX is trading 31.5% down today after $15M dilutive offering and trial failure fallout
ELTX is trading 31.5% down now at $3.52 after a deeply dilutive $15 million registered direct offering and continued selling pressure from its failed Phase 2...
🔴 ELTX is trading 20.6% down today following a $15 million offering and Phase 2 trial failure
ELTX is trading at $4.08 (20.55% down) in pre-market following a $15 million registered direct offering and continued fallout from disappointing clinical trial...
🔴 ELTX Trading Down 5.8% Amid Class Action Lawsuit Investigations Following Clinical Trial Failure
ELTX is trading at $4.84 (5.8% down) in after-hours trading, extending its volatility. • The decline on July 1, 2026, comes as two law firms, Pomerantz LLP...
Elicio Therapeutics Bounces 17% After a Brutal Trial Miss — But Can a Post-Hoc Silver Lining Save a Cash-Strapped Company?
Shares of Elicio Therapeutics surged +16.9% to $4.57 on July 1, defying a softer broad market, as bargain hunters piled into a micro-cap biotech still reeling...
🟢 ELTX is trading 16.85% up today as it rebounds from ELI-002 pancreatic cancer data selloff
ELTX is trading at $4.57 (+16.85%) as buyers step back in following a sharp decline linked to recent clinical trial results. • The stock is seeing a volatile...
🟢 ELTX is trading 6.1% up today as it rebounds on continued pancreatic cancer data buzz
ELTX is trading 6.1% up at $4.15 in pre-market as the micro-cap biotech rebounds from a recent pullback amid ongoing optimism surrounding its pancreatic cancer...